Safety of DNP007 in Healthy Volunteers
Part of Digestive system clinical trials.
This study tests the safety of a new drug called DNP007 in healthy volunteers. It is a Phase 1 trial, meaning it's one of the first steps in humans to see if the drug is safe and how the body handles it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must weigh between 50 and 95 kg (110 to 209 lbs) and have a BMI between 18 and 30.
- You cannot have any serious medical conditions (like liver, kidney, heart, or mental health problems) or a history of them.
- You cannot have taken any prescription or herbal medications in the last 2 weeks, or over-the-counter drugs, vitamins, or supplements in the last week.
- You must be a non-smoker (or have quit for at least 3 months) and not drink more than 21 alcoholic drinks per week.
- You cannot have donated blood or had an infection within the last 1 to 2 months, depending on the type.
- You must be willing to use effective birth control during the study and for 4 weeks after, and agree not to donate sperm.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DNP002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if DNP002 is safe and can help shrink tumors or slow their growth.
This research study tests how a new medicine (NNC0487-0111) moves through your body and how well you tolerate it. The study compares people with healthy livers to people with reduced liver function to understand if liver disease affects how the medicine works.
This study tests how the body processes and tolerates a new experimental drug (MDR-001) in people with mild to moderate liver disease. The research helps doctors understand if the drug is safe and how it works when liver function is reduced.
This early-phase study tests whether ALN-PNP is safe and well tolerated, first in healthy adults and then in adults with MASLD (fatty liver disease). If you have MASLD, it may help researchers learn whether this medicine is a promising option for treating liver fat buildup.
This is an early-stage safety study testing a new experimental drug called ATH-097 in healthy volunteers. Researchers will give increasing doses to small groups to learn how the drug is tolerated and processed by the body.
This trial tests how a drug called D-2570 is processed in people with different levels of liver function. It compares people with liver impairment to those with healthy livers to see how the drug moves through the body.
Hear when a new Liver Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.